

## Supporting information

### Reversing activity of cancer associated fibroblast for staged glycolipid micelles

#### against internal breast tumor cells

Yun Zhu,<sup>†</sup> Fangying Yu,<sup>‡</sup> Yanan Tan,<sup>†</sup> Yun Hong,<sup>§</sup> Tingting Meng,<sup>‡</sup> Yupeng Liu,<sup>‡</sup> Suhuan Dai,<sup>‡</sup> Guoxi Qiu,<sup>‡</sup> Hong Yuan,<sup>‡</sup> and Fuqiang Hu<sup>\*†‡</sup>

<sup>‡</sup>College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, People's Republic of China.


<sup>†</sup> Ocean College, Zhejiang University, 1 Zheda Road, Zhoushan 316021, People's Republic of China.

<sup>§</sup> The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310058, China


\*Corresponding Author: Prof. Fuqiang Hu

Tel/Fax: +86-571-88208439


E-mail: hufq@zju.edu.cn




**Figure S1.** The  $^1\text{H}$  NMR spectroscopy of synthesized glycolipid polymer.




**Figure S2.** CMC value of GLPM in aqueous medium.




**Figure S3.** The size of GLPM, GLPM/DOX and GLPM/Tel measured by DLS.




**Figure S4.** Drug release profiles of Tel, DOX, GLPM/Tel and GLPM/DOX after incubation with pH 7.4 PBS (10% fetal bovine serum).




**Figure S5.** The activation of normal NIH/3T3 cells by supernatant collected from MCF-7 cells.




**Figure S6.** Semi-quantitative analysis of expressed α-SMA in activated NIH/3T3 cells after different drugs treatment.




**Figure S7.** Semi-quantitative analysis of expressed CTGF in activated NIH/3T3 cells after different drugs treatment.




**Figure S8.** The anti-angiogenic efficacy of Tel and GLPM/Tel on HUVEC cell line *in vitro*.




**Figure S9.** Quantitative analysis of intracellular HA after drugs treatment for 48h.



**Figure S10.** Cytotoxicity evaluation of Tel and GLPM/Tel on activated NIH/3T3 cell.




**Figure S11.** Cytotoxicity evaluation of Tel and GLPM/Tel on MCF-7 cell.




**Blue: cell nucleus    Green:  $\alpha$ -SMA    Red: CD31**


**Figure S12.** Immunofluorescent staining for the pathological structure on MCF-7 tumor mass.




**Figure S13.** Z-stack images of penetration of GLPM/DOX in MCTSs composed of 4T1 cells and activated NIH/3T3 cells were visualized by confocal microscopy after PBS, Tel and GLPM/Tel treatment for 2 days. Bars: 100 μm.




**Figure S14.** Antitumor efficacy of different drugs on MCTSs measured by PI staining.




**Figure S15.** The correlation between  $\alpha$ -SMA and CD31 calculated by imageJ software.




**Figure S16.** The correlation between  $\alpha$ -SMA and DiI calculated by imageJ software.




**Figure S17.** The correlation between CD31 and DiI calculated by imageJ software.




**Figure S18.** The volumes of MCF-7 tumor during saline, Tel and GLPM/Tel treatments.



**Figure S19.** The weight of MCF-7 tumor masses after saline, Tel and GLPM/Tel treatment for three times. \*\* $p < 0.01$ , \*\*\* $p < 0.001$  as determined by two-tailed student's t-test.



**Figure S20.** The weight of mice during drugs treatment.



**Figure S21.** HE staining for major organs after drugs treatment.

**Table S1.** Depth of MCTSs after drugs treatment.

	PBS	Tel	GLPM/Tel	GLPM/DOX	GLPM/Tel+ GLPM/DOX	GLPM/Tel+ combinational therapy
<b>Penetration Depth</b>	70 $\mu$ m	140 $\mu$ m	140 $\mu$ m	/	/	/
<b>Apoptosis ratio</b>	6.2%	/	13.0%	30.3%	37.3%	53.5%